These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32660904)

  • 1. Complete Response of a Young Woman With MYD88
    Pabon CM; Neff JL; Forns TE; Wang J
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 5. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waldenström macroglobulinemia.
    Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
    Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
    Castellani F; Visentin A; Campagnolo M; Salvalaggio A; Cacciavillani M; Candiotto C; Bertorelle R; Trentin L; Briani C
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32284437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
    Hartsell L; Janes A; Larck C; Park S; Arnall JR
    J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for the treatment of Waldenström macroglobulinemia.
    Despina F; Meletios Athanasios D; Efstathios K
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report.
    Gravesen CD; Chanchiri I; Kristensen IB; Jensen MB; Harbo FSG; Dahlrot RH
    J Med Case Rep; 2024 Sep; 18(1):424. PubMed ID: 39256774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib in the management of Waldenstrom macroglobulinemia.
    Yosef A; Touloukian EZ; Nambudiri VE
    J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waldenstrom Macroglobulinemia Manifesting as Acute Kidney Injury and Bing-Neel Syndrome With Excellent Response to Ibrutinib.
    Jafri H; Khan I; Sidda A; Khan NAJ; Kheetan M; Griswold D; Pacioles T
    J Investig Med High Impact Case Rep; 2021; 9():23247096211021228. PubMed ID: 34078157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
    Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
    Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
    Treon SP; Meid K; Gustine J; Yang G; Xu L; Liu X; Patterson CJ; Hunter ZR; Branagan AR; Laubach JP; Ghobrial IM; Palomba ML; Advani R; Castillo JJ
    J Clin Oncol; 2021 Feb; 39(6):565-575. PubMed ID: 32931398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
    Richardson K; Castillo JJ; Sarosiek SR; Branagan AR; Flynn CA; Meid K; Gustine JN; Liu X; Kofides A; Liu S; Wolf JL; Kacena KA; Patterson CJ; Guerrera ML; Tsakmaklis N; Treon SP; Hunter ZR
    Blood Adv; 2024 May; 8(9):2133-2137. PubMed ID: 38237078
    [No Abstract]   [Full Text] [Related]  

  • 17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bing-Neel Syndrome: Update on the Diagnosis and Treatment.
    Nanah A; Al Hadidi S
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e213-e219. PubMed ID: 34674984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.